Tapros Tafluprost Eye Drops

1. Indications and Usage
Ocular Hypertension: Indicated for lowering elevated intraocular pressure (IOP) in patients with ocular hypertension.
Open-Angle Glaucoma: Indicated for lowering elevated IOP in patients with open-angle glaucoma.
2. Dosage and Administration
Route of Administration: For topical ophthalmic use ONLY.
Standard Dosage: One drop in the affected eye(s) once daily.
Critical Administration Instructions:
Timing: Daily administration should not exceed once daily. More frequent administration may decrease the IOP-lowering effect.
Multiple Ophthalmic Drugs: If using other topical ophthalmic drugs, administer at intervals of at least 5 minutes.
Storage: Unopened single-dose containers must be refrigerated (2°C to 8°C). Once the foil pouch is opened, it may be kept at room temperature (up to 25°C) for up to 1 month.
Hygiene: Each single-dose container is for single use only. Discard any remaining solution immediately after use.
3. Mechanism of Action
FP Receptor Agonism: Tafluprost is a fluorinated analog of prostaglandin F2α and acts as a selective agonist at the FP prostanoid receptor.
Aqueous Humor Outflow: It lowers intraocular pressure by increasing the outflow of aqueous humor, primarily through the uveoscleral pathway.
4. Safety and Warnings
Pigment Deposition: May cause irreversible iris hyperpigmentation and reversible pigmentation changes in periorbital tissues (eyelids) and eyelashes.
Inflammation: Use with caution in patients with active intraocular inflammation (e.g., uveitis, iritis), as it may exacerbate the condition.
Macular Edema: Use with caution in aphakic patients, pseudophakic patients with torn posterior capsules of the crystalline lens, and patients at risk of cystoid macular edema.
Respiratory Effects: Use with caution in patients with bronchial asthma or a history of asthma, as prostaglandin analogs may induce bronchospasm.
Contact Lenses: Patients should not wear contact lenses during treatment.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Conjunctival hyperemia (4%–20%), eyelid hyperpigmentation, eyelash abnormalities (increased length, thickness, and number), and eye irritation.
Clinical Research Highlights: Clinical trials have demonstrated that tafluprost 0.0015% provides significant and sustained reduction in intraocular pressure with a favorable safety profile.
6. Drug Interactions
Other Ophthalmic Agents: No formal pharmacokinetic interactions have been established. However, when used with other topical ophthalmic agents, a minimum interval of 5 minutes is required to prevent washout.
Preservatives: Caution is advised when co-administering with other eye drops containing preservatives (e.g., benzalkonium chloride) to avoid cumulative ocular surface toxicity.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Tafluprost. Excipients: Polysorbate 80, sodium dihydrogen phosphate, sodium hydroxide, and water for injection.
Appearance: Clear, colorless solution.
Packaging: Available in single-dose containers (e.g., 0.0015%) sealed within foil pouches.
Storage: Store in a refrigerator at 2°C to 8°C. Protect from light.